More than 600,000 bottles of the blood pressure medication ramipril have been recalled across the United States due to concerns about potential contamination. The recall was issued by the FDA after discovering that ingredients were sourced from an unapproved and uninspected manufacturing facility in India.
Ramipril is a commonly prescribed ACE inhibitor used to treat high blood pressure and reduce the risk of heart attack, stroke, and kidney damage. Each year, more than 2.4 million Americans rely on the medication, making the recall significant for patients and healthcare providers nationwide.
The affected products were manufactured by Lupin Pharmaceuticals and include ramipril capsules in 2.5 mg, 5 mg, and 10 mg strengths. Bottles containing 90, 100, or 500 capsules with expiration dates through July 2026 are included in the recall and were widely distributed through pharmacies and hospitals.
The FDA stated that the recall was issued out of caution, as ingredients from uninspected facilities may not meet required safety and quality standards. No adverse health events linked to the recalled medication have been reported so far.
Patients are advised not to stop taking ramipril abruptly, as doing so could cause dangerous spikes in blood pressure. Instead, they should check their medication labels and contact their pharmacist or healthcare provider if their bottle matches the recalled batches.
Pharmacies may offer replacement medication, and doctors can prescribe alternative ACE inhibitors such as lisinopril or enalapril if needed. Patients experiencing unusual symptoms should report them to their healthcare provider and the FDA’s MedWatch program.
The recall highlights the importance of strict oversight in the global pharmaceutical supply chain, where ingredients often come from multiple countries. Regular inspections help ensure medications remain safe and effective.
While the recall may cause temporary concern, regulators emphasize that proactive action helps protect patients. With proper guidance from healthcare providers, most patients can continue managing their blood pressure safely.
